scholarly journals 1049 – Increasing Incidence of Left Sided Colorectal Cancer in the Young: Age is Not the Only Factor

2019 ◽  
Vol 156 (6) ◽  
pp. S-1431-S-1432
Author(s):  
David Kearney ◽  
Christy E. Cauley ◽  
Alexandra Aiello ◽  
Matthew Kalady ◽  
James M. Church ◽  
...  
Keyword(s):  
2005 ◽  
Vol 128 (4) ◽  
pp. 1067-1076 ◽  
Author(s):  
Jonathan P. Terdiman
Keyword(s):  

2019 ◽  
Vol 43 (5) ◽  
pp. 477-486 ◽  
Author(s):  
Andrea C.B. Silva ◽  
Maria Fernanda B. Vicentini ◽  
Elizabeth Z. Mendoza ◽  
Fernanda K. Fujiki ◽  
Leonardo G. da Fonseca ◽  
...  

2020 ◽  
pp. 1-12
Author(s):  
Xuelian Lei ◽  
Shuailing Song ◽  
Xiao Li ◽  
Chong Geng ◽  
Chunhui Wang

2011 ◽  
Vol 29 (20) ◽  
pp. 2781-2786 ◽  
Author(s):  
Charles D. Blanke ◽  
Brian M. Bot ◽  
David M. Thomas ◽  
Archie Bleyer ◽  
Claus-Henning Kohne ◽  
...  

Purpose Colorectal cancer predominantly occurs in the elderly, but approximately 5% of patients are 50 years old or younger. We sought to determine whether young age is prognostic, or whether it influences efficacy/toxicity of chemotherapy, in patients with advanced disease. Methods We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy. End points included progression-free survival (PFS), overall survival (OS), response rate (RR), and grade 3 or worse adverse events. Stratified Cox and adjusted logistic-regression models were used to test for age effects and age-treatment interactions. Results A total of 793 patients (13%) were younger than 50 years old; 188 of these patients (3% of total patients) were younger than 40 years old. Grade 3 or worse nausea (10% v 7%; P = .01) was more common, and severe diarrhea (11% v 14%; P = .001) and neutropenia (23% v 26%; P < .001) were less common in young (younger than 50 years) than in older (older than 50 years) patients. Age was prognostic for PFS, with poorer outcomes occurring in those younger than 50 years (median, 6.0 v 7.5 months; hazard ratio, 1.10; P = .02), but it did not affect RR or OS. In the subset of monotherapy versus combination chemotherapy trials, the relative benefits of multiagent chemotherapy were similar for young and older patients. Results were comparable when utilizing an age cut point of 40 years. Conclusion Young age is modestly associated with poorer PFS but not OS or RR in treated patients with aCRC, and young patients have more nausea but less diarrhea and neutropenia with chemotherapy in general. Young versus older patients derive the same benefits from combination chemotherapy. Absent results of a clinical trial, standard combination chemotherapy approaches are appropriate for young patients with aCRC.


2001 ◽  
Vol 93 (14) ◽  
pp. 1106-1108 ◽  
Author(s):  
S. Kong ◽  
Q. Wei ◽  
C. I. Amos ◽  
P. M. Lynch ◽  
B. Levin ◽  
...  

2014 ◽  
Vol 10 (Issue 1-2) ◽  
pp. 6-11
Author(s):  
Shawky El Haddad ◽  
Iman Abdel Hady ◽  
Amr Sakr ◽  
Tamer El-Nahas ◽  
Ahmed Rashad

Sign in / Sign up

Export Citation Format

Share Document